In 670 biologic-naïve adults with active psoriatic arthritis, oral deucravacitinib 6 mg once daily beat placebo for ACR20 at week 16 (54.2% vs 34.1%, P<.001), with responses increased at week 52 and low serious adverse events (1.8% vs 2.4%).
RCTn = 670
van der Heijde et al. Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial